Selank potential benefits and areas of research

Selank's claimed benefit is anxiolysis — reduction of anxiety — without the sedation, cognitive dulling, and dependence associated with benzodiazepines. That claim rests on a small number of Russian clinical comparisons against benzodiazepines, plus a substantial preclinical literature from the same research tradition.

It is worth being precise about scale here, because "clinically studied anxiolytic" and "studied in fewer than 200 patients across a couple of trials in one country" are both accurate descriptions of the same evidence base, and only one of them is usually offered.

Structurally, Selank is the tuftsin sequence with a proline-glycine-proline tail added for stability: Thr-Lys-Pro-Arg-Pro-Gly-Pro (Protein & Peptide Letters 2018; PMID 30255741).

The foundational study compared Selank with the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia — 30 on Selank, 32 on medazepam. Anxiolytic effects of the two drugs were reported as similar, with Selank additionally described as having antiasthenic and psychostimulant effects. Treatment also increased measured enkephalin activity, particularly in the generalized anxiety disorder patients (Zh Nevrol Psikhiatr Im S S Korsakova 2008; PMID 18454096).

A second comparison, against phenazepam in 60 patients with phobic-anxiety and somatoform disorders, reported pronounced anxiolytic and mild nootropic effects, and noted that the anxiolytic effect persisted for a week after the last dose (Zh Nevrol Psikhiatr Im S S Korsakova 2014; PMID 25176261).

Both trials used an active comparator rather than placebo. That design answers "is this as good as a benzodiazepine" but cannot measure the placebo response in this population — and anxiety is among the conditions with the largest placebo effects in psychiatry.

The cognitive claims for Selank are secondary observations from anxiety trials, not findings from trials designed to test cognition. The 2014 phenazepam comparison describes "mild nootropic effects"; the 2008 trial describes "psychostimulant" effects alongside anxiolysis.

There is a plausible and unglamorous reading of this: reducing anxiety improves attention and subjective clarity, which would look like a nootropic effect without requiring a separate cognitive mechanism. Nothing in the published human literature distinguishes those two explanations, and no trial has tested Selank for cognitive enhancement in people without an anxiety diagnosis.

The most concrete mechanistic finding comes from radioligand binding work showing that Selank acts as a positive allosteric modulator of GABA binding — the same broad receptor system benzodiazepines act on, though at what appears to be a different, only partially overlapping site. Selank was able to block the modulatory activity of diazepam and olanzapine in that system, suggesting the binding locations are related but not identical (Vyunova et al., Protein & Peptide Letters 2018; PMID 30255741).

That is genuinely interesting, and it is a laboratory membrane-binding study, not a demonstration of how the peptide produces clinical benefit. Other proposed mechanisms in the Russian literature involve enkephalin metabolism, BDNF, serotonergic signalling, and immune-related pathways inherited from its tuftsin origin — each supported by preclinical work of varying strength.

• Not approved by the FDA or EMA; registration is regional.
• Total published human exposure is on the order of a hundred-odd patients across a few small trials.
• Both key trials used active comparators, so the placebo response is unmeasured.
• Full methods exist in Russian; the international record is an indexed abstract, which limits outside appraisal of randomisation and analysis.
• Studied patients carried clinical diagnoses. Nothing addresses subclinical stress or focus in healthy adults — the use most often marketed.
• The studied route is intranasal. Injectable "Selank" sold internationally is not the formulation these trials used.